pargyline has been researched along with Cognitive Decline in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, YX | 1 |
| Wang, H | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 1 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 1 |
| Li, J | 1 |
| Zhang, HY | 1 |
| Mao, F | 1 |
1 other study available for pargyline and Cognitive Decline
| Article | Year |
|---|---|
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |